Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor
- PMID: 12023535
- DOI: 10.1124/jpet.301.3.1033
Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor
Abstract
Xanomeline is a potent agonist that is functionally selective for muscarinic M(1) receptors. We have shown previously that a significant fraction of xanomeline binding to membranes of Chinese hamster ovary (CHO) cells expressing the M(1) receptors occurs in a wash-resistant manner and speculated that this persistent binding likely does not take place at the primary binding site on the receptor. In the present work we investigated in depth the pharmacological characteristics of this unique mode of xanomeline binding and the effects of this binding on the interaction of classical competitive ligands with the receptor in CHO cells that express the M(1) muscarinic receptor. Onset of persistent binding of xanomeline to the M(1) muscarinic receptor was fast and was only slightly hindered by atropine. Its dissociation was extremely slow, with a half-life of over 30 h. Although persistently bound xanomeline strongly inhibited binding of the classical antagonist N-methylscopolamine (NMS) to the receptor, there are multiple indications that this is not the result of competition at the same binding domain. Namely, wash-resistant binding of xanomeline only slightly slowed the rate of NMS association, but enhanced the rate of NMS dissociation. Moreover, preincubation with xanomeline followed by extensive washing brought about an apparent decrease in the number of NMS binding sites. Our findings are best interpreted in terms of allosteric interactions between xanomeline-persistent binding to the M(1) muscarinic receptor and competitive ligands bound to the classical receptor binding site.
Similar articles
-
On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.Mol Pharmacol. 1998 Jun;53(6):1120-30. Mol Pharmacol. 1998. PMID: 9614217
-
Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.Neurosci Lett. 2006 Dec 13;410(1):11-4. doi: 10.1016/j.neulet.2006.09.062. Epub 2006 Oct 18. Neurosci Lett. 2006. PMID: 17052840 Free PMC article.
-
Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.J Pharmacol Exp Ther. 1999 Jun;289(3):1220-8. J Pharmacol Exp Ther. 1999. PMID: 10336509
-
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.CNS Drug Rev. 2003 Summer;9(2):159-86. doi: 10.1111/j.1527-3458.2003.tb00247.x. CNS Drug Rev. 2003. PMID: 12847557 Free PMC article. Review.
-
The antipsychotic potential of muscarinic allosteric modulation.Drug News Perspect. 2010 May;23(4):229-40. doi: 10.1358/dnp.2010.23.4.1416977. Drug News Perspect. 2010. PMID: 20520852 Free PMC article. Review.
Cited by
-
Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.PLoS One. 2010 Dec 23;5(12):e15722. doi: 10.1371/journal.pone.0015722. PLoS One. 2010. PMID: 21203415 Free PMC article.
-
Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.PLoS One. 2014 Feb 18;9(2):e88910. doi: 10.1371/journal.pone.0088910. eCollection 2014. PLoS One. 2014. PMID: 24558448 Free PMC article.
-
Immediate and delayed consequences of xanomeline wash-resistant binding at the M3 muscarinic receptor.Neurochem Res. 2009 Jun;34(6):1138-49. doi: 10.1007/s11064-008-9886-3. Epub 2008 Dec 12. Neurochem Res. 2009. PMID: 19082883 Free PMC article.
-
Xanomeline and Trospium: A Potential Fixed Drug Combination (FDC) for Schizophrenia-A Brief Review of Current Data.Innov Clin Neurosci. 2022 Oct-Dec;19(10-12):43-47. Innov Clin Neurosci. 2022. PMID: 36591549 Free PMC article. Review.
-
Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.PLoS One. 2012;7(5):e36319. doi: 10.1371/journal.pone.0036319. Epub 2012 May 1. PLoS One. 2012. PMID: 22563490 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources